01
Cash & equivalents decreased 60.3%
Cash & equivalents changed -60.3% from the comparable as-filed period.
$8.8M→$3.5MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTFibroBiologics, Inc.'s latest supported as-filed period reports net income of -$4.1M, 11.6% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -60.3% from the comparable as-filed period.
Net income changed +11.6% from the comparable as-filed period.
Operating income changed +10.2% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
FBLG · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-362027SEC ↗10-QJul 31, 2026Period Jun 30, 20260001193125-26-328454SEC ↗8-KJul 24, 2026Period Jul 22, 20260001193125-26-316067SEC ↗8-KJul 9, 2026Period Jul 2, 20260001193125-26-299290SEC ↗8-KJun 29, 2026Period Jun 25, 20260001193125-26-288468SEC ↗4Jun 23, 2026Period Jun 23, 20260001493152-26-029851SEC ↗4Jun 23, 2026Period Jun 23, 20260001493152-26-029850SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 23, 2026Filed Jun 23, 2026 | Hoffman Robert E.Director | Grant Or AwardDirect | 30,803 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -18.8% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Stock-based compensation changed -3.0% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001493152-26-029849